Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus

Human papillomavirus (HPV) types 16 and 18 cause 70% of cervical cancer cases globally. The nonavalent HPV vaccine (9vHPV) was licensed in 2014 and protects against the next five most common cancer-causing HPV types (HPV 31/33/45/52/58) after HPV 16/18. Phase III clinical studies have demonstrated h...

Descripción completa

Detalles Bibliográficos
Autores principales: Toh, Zheng Quan, Kosasih, Jennie, Russell, Fiona M, Garland, Suzanne M, Mulholland, Edward K, Licciardi, Paul V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613616/
https://www.ncbi.nlm.nih.gov/pubmed/31308715
http://dx.doi.org/10.2147/IDR.S178381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613616/
https://www.ncbi.nlm.nih.gov/pubmed/31308715
http://dx.doi.org/10.2147/IDR.S178381

Ejemplares similares